First results of the GMMG-CONCEPT trial for multiple myeloma

Iberdomide in combination with dexamethasone for multiple myeloma

PLEIADES: Daratumumab combinations for multiple myeloma

Treatment options for high risk relapsed/refractory multiple myeloma

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma

Introduction of the biosimilar trastuzumab and its impact on patients and services

Practical guidance on the assessment of biosimilar monoclonal antibodies: A physician's perspective

Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma

Transitioning from bortezomib to ixazomib in patients with multiple myeloma

Evaluating treatment options for acute myeloid leukaemia